Other languages Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-06 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-1.57%		-3.85%	-21.38%

May. 30	Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	CI
May. 24	Cyclo Therapeutics Files $100 Million Mixed Shelf	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	May. 30
Cyclo Therapeutics Files $100 Million Mixed Shelf	May. 24
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	Mar. 14
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	Dec. 27
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	Dec. 27
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	Dec. 26
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	Dec. 18
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	Nov. 10
Top Premarket Decliners	Nov. 10
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	23-09-21
Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board	23-08-21
Cyclo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Cyclo Therapeutics Says European Patent Office Grants Allowance of Trappsol Cyclo Patent; Shares Rise	23-06-12
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings	23-06-05
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Other languages

Filters